



Agonistas del receptor Glp-1: Desde su efecto fisiológico en el sistema incretina hasta el rol en enfermedad renal diabética

2021

text (article)

Analítica

Diabetes Mellitus is a very prevalent disease with a high risk of micro and macrovascular complications. Up to 20 - 40% of diabetic patients develop diabetic kidney disease at some point in their evolution. Recently, hypoglycemic treatment is not only aimed at glycemic control, but also at impacting cardiovascular and kidney outcomes. Among these molecules, we find the GLP-1 analogs (Type 1 glucagon-like peptide), considered a mainstay in hypoglycemic treatment for diabetic patients with cardiovascular disease. Objective: To describe the main clinical aspects of GLP-1 agonists, their mechanism of action and their physiological role in the cardiovascular and renal outcomes of diabetes mellitus. Methodology: An advanced search was carried out with the DeCS terms: "Diabetic Nephropathy; GLP-1 Receptor Agonists, Glucagon-Like Peptides; Diabetes Mellitus" using the Clinical Key, Embase, PubMed and Ovid search engines, obtaining a total of 413 results, among original articles, case reports, case series and literature reviews, a total of 72 articles were selected used for the preparation of the literature review. Conclusion: Therapies based on GLP-1 analogues in diabetes mellitus are a therapeutic mainstay in individuals with risk factors for diabetic kidney disease, due to its proven benefits in reducing composite kidney outcomes

Diabetes Mellitus is a very prevalent disease with a high risk of micro and macrovascular complications. Up to 20 - 40% of diabetic patients develop diabetic kidney disease at some point in their evolution. Recently, hypoglycemic treatment is not only aimed at glycemic control, but also at impacting cardiovascular and kidney outcomes. Among these molecules, we find the GLP-1 analogs (Type 1 glucagon-like peptide), considered a mainstay in hypoglycemic treatment for diabetic patients with cardiovascular disease. Objective: To describe the main clinical aspects of GLP-1 agonists, their mechanism of action and their physiological role in the cardiovascular and renal outcomes of diabetes mellitus. Methodology: An advanced search was carried out with the DeCS terms: "Diabetic Nephropathy; GLP-1 Receptor Agonists, Glucagon-Like Peptides; Diabetes Mellitus" using the Clinical Key, Embase, PubMed and Ovid search engines, obtaining a total of 413 results, among original articles, case reports, case series and literature reviews, a total of 72 articles were selected used for the preparation of the literature review. Conclusion: Therapies based on GLP-1 analogues in diabetes mellitus are a therapeutic mainstay in individuals with risk factors for diabetic kidney disease, due to its proven benefits in reducing composite kidney outcomes

Título: Agonistas del receptor Glp-1: Desde su efecto fisiológico en el sistema incretina hasta su rol en enfermedad renal diabética [electronic resource]

Editorial: 2021

Tipo Audiovisual: Nefropatía diabética Agonistas del receptor GLP-1 Péptidos similares al glucagón Diabetes mellitus Diabetic nephropathy GLP-1 receptor agonists Glucagon-like peptides Diabetes

Documento fuente: Archivos de medicina, ISSN 1698-9465, Vol. 17, N°. 2, 2021

Nota general: application/pdf

Restricciones de acceso: Open access content. Open access content star

Condiciones de uso y reproducción: LICENCIA DE USO: Los documentos a texto completo incluidos en Dialnet son de acceso libre y propiedad de sus autores y/o editores. Por tanto, cualquier acto de reproducción, distribución, comunicación pública y/o transformación total o parcial requiere el consentimiento expreso y escrito de aquéllos. Cualquier enlace al texto completo de estos documentos deberá hacerse a través de la URL oficial de éstos en Dialnet. Más información: <https://dialnet.unirioja.es/info/derechosOAI> | INTELLECTUAL PROPERTY RIGHTS STATEMENT: Full text documents hosted by Dialnet are protected by copyright and/or related rights. This digital object is accessible without charge, but its use is subject to the licensing conditions set by its authors or editors. Unless expressly stated otherwise in the licensing conditions, you are free to linking, browsing, printing and making a copy for your own personal purposes. All other acts of reproduction and communication to the public are subject to the licensing conditions expressed by editors and authors and require consent from them. Any link to this document should be made using its official URL in Dialnet. More info: <https://dialnet.unirioja.es/info/derechosOAI>

Lengua: Spanish

Enlace a fuente de información: Archivos de medicina, ISSN 1698-9465, Vol. 17, N°. 2, 2021

Baratz Innovación Documental

- Gran Vía, 59 28013 Madrid
- (+34) 91 456 03 60
- informa@baratz.es